Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6 Suppl 14
|
pubmed:dateCreated |
1997-2-4
|
pubmed:abstractText |
The approach to treatment for advanced prostate cancer patients who have failed to respond to therapy with androgen deprivation has undergone a significant and fundamental transformation over the last 3 years, beginning with the description of the flutamide-withdrawal syndrome in 1993. This was the same year that the Cancer and Leukemia Group B Prostate Cancer Committee was created. This committee has been studying the following two important areas in advanced prostate cancer the optimal treatment and biology of androgen-independent, yet hormonally sensitive, prostate cancer; and the optimal treatment for patients with truly hormone-refractory disease. Important biologic and quality of life correlative trials will complement the clinical information gained, with the goal of providing further insight into the extremely complex biological processes involved.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0093-7754
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
23
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
28-31
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading | |
pubmed:year |
1996
|
pubmed:articleTitle |
Cancer and Leukemia Group B trials for advanced prostate cancer.
|
pubmed:affiliation |
University of California, San Francisco, School of Medicine, USA.
|
pubmed:publicationType |
Journal Article,
Review
|